Gen9 Awarded Two Cornerstone Patents For BioFab DNA Assembly Technology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gen9, Inc., a pioneer in DNA synthesis and assembly technology, today announced the issuance of two new U.S. patents that further expand its industry-leading portfolio of intellectual property.
“As the first and only company to develop and operate an industrialized, massively-parallel manufacturing platform for DNA synthesis and assembly, Gen9 has driven innovation across a number of critical areas, enabling us to produce high-quality DNA at a scale, construct length and value never before possible”
The patents, U.S. Patent Nos. 9,023,601 and 9,051,666, provide broad protection for features that are at the heart of Gen9’s proprietary DNA synthesis and assembly technology. Among other aspects, the patents cover novel processes, compositions and devices directed to DNA fragments designed for use in DNA assembly, as well as amplification of engineered fragments of longer-length DNA sequences. They represent the newest additions to Gen9’s robust patent estate uniquely geared toward making high-fidelity synthetic genes accessible to the greater synthetic biology community.
“As the first and only company to develop and operate an industrialized, massively-parallel manufacturing platform for DNA synthesis and assembly, Gen9 has driven innovation across a number of critical areas, enabling us to produce high-quality DNA at a scale, construct length and value never before possible,” said Devin Leake, Gen9 Vice President of Research and Development and Operations. “These new patents represent some of the unique technologies that power our BioFab® platform, allowing us to meet the soaring demand in synthetic biology.”
“We believe synthetic biology will fuel the future of advancements in everything from therapeutics to clean technology to agriculture,” said Kevin Munnelly, President and CEO of Gen9. “We are dedicated to the further development of transformative DNA production technologies and are excited to continue working with our customers as they put the power of synthetic biology to work.”
Gen9 is the premier next-generation DNA synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, MA, and can be found online at www.gen9bio.com.
Gen9, GeneBit, GeneByte and BioFab are registered trademarks of Gen9, Inc.
Colin Sanford, 203-918-4347